CA2927565C - Combination therapies - Google Patents

Combination therapies Download PDF

Info

Publication number
CA2927565C
CA2927565C CA2927565A CA2927565A CA2927565C CA 2927565 C CA2927565 C CA 2927565C CA 2927565 A CA2927565 A CA 2927565A CA 2927565 A CA2927565 A CA 2927565A CA 2927565 C CA2927565 C CA 2927565C
Authority
CA
Canada
Prior art keywords
combination therapies
therapies
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2927565A
Other languages
English (en)
French (fr)
Other versions
CA2927565A1 (en
Inventor
Daniel P. Gold
Guillermo Garcia-Manero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of CA2927565A1 publication Critical patent/CA2927565A1/en
Application granted granted Critical
Publication of CA2927565C publication Critical patent/CA2927565C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2927565A 2012-10-30 2013-10-30 Combination therapies Expired - Fee Related CA2927565C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720346P 2012-10-30 2012-10-30
US61/720,346 2012-10-30
PCT/US2013/067607 WO2014070948A1 (en) 2012-10-30 2013-10-30 Combination therapies

Publications (2)

Publication Number Publication Date
CA2927565A1 CA2927565A1 (en) 2014-05-08
CA2927565C true CA2927565C (en) 2021-05-18

Family

ID=50628036

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2927565A Expired - Fee Related CA2927565C (en) 2012-10-30 2013-10-30 Combination therapies

Country Status (16)

Country Link
US (2) US20150258068A1 (enExample)
EP (2) EP3662911A1 (enExample)
JP (1) JP6343285B2 (enExample)
CA (1) CA2927565C (enExample)
CY (1) CY1123043T1 (enExample)
DK (1) DK2914254T3 (enExample)
ES (1) ES2774296T3 (enExample)
HR (1) HRP20200521T1 (enExample)
HU (1) HUE048584T2 (enExample)
LT (1) LT2914254T (enExample)
PL (1) PL2914254T3 (enExample)
PT (1) PT2914254T (enExample)
RS (1) RS60122B1 (enExample)
SI (1) SI2914254T1 (enExample)
SM (1) SMT202000168T1 (enExample)
WO (1) WO2014070948A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349664B (en) 2003-09-22 2011-10-01 S Bio Pte Ltd Benzimidazole derivatives: preparation and pharmaceutical applications
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
AR108257A1 (es) * 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3749330A4 (en) 2018-02-06 2021-11-17 The General Hospital Corporation REPEATED PATTERN RNA USED AS BIOMARKERS OF TUMOR IMMUNE RESPONSE
SG11202105506UA (en) * 2018-11-30 2021-06-29 Mei Pharma Inc Combination therapies for high and very high risk mds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20100098691A1 (en) * 2001-01-24 2010-04-22 S'bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
AU2003215112A1 (en) 2002-02-07 2003-09-02 Axys Pharmaceuticals Novel bicyclic hydroxamates as inhibitors of histone deacetylase
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
WO2007030080A1 (en) * 2005-09-08 2007-03-15 S*Bio Pte Ltd Heterocyclic compounds
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN102369204A (zh) * 2008-09-26 2012-03-07 新加坡科技研究局 3-脱氮瓶菌素衍生物

Also Published As

Publication number Publication date
CY1123043T1 (el) 2021-10-29
EP2914254A4 (en) 2016-06-29
SI2914254T1 (sl) 2020-07-31
CA2927565A1 (en) 2014-05-08
US20150258068A1 (en) 2015-09-17
HRP20200521T1 (hr) 2020-08-07
SMT202000168T1 (it) 2020-05-08
US20210100775A1 (en) 2021-04-08
ES2774296T3 (es) 2020-07-20
EP3662911A1 (en) 2020-06-10
LT2914254T (lt) 2020-04-27
JP6343285B2 (ja) 2018-06-13
WO2014070948A1 (en) 2014-05-08
DK2914254T3 (en) 2020-03-30
EP2914254B1 (en) 2020-01-08
RS60122B1 (sr) 2020-05-29
JP2016501838A (ja) 2016-01-21
HUE048584T2 (hu) 2020-08-28
EP2914254A1 (en) 2015-09-09
PT2914254T (pt) 2020-04-02
PL2914254T3 (pl) 2020-09-07

Similar Documents

Publication Publication Date Title
CA2927565C (en) Combination therapies
GB201214493D0 (en) Therapies
AU2012902628A0 (en) SwiftLink
AU2012902533A0 (en) Uni-gen
AU2012902409A0 (en) ADDinApp ADD2APP
AU2012902401A0 (en) eReceipts
AU2012902338A0 (en) PowderME
AU2012902149A0 (en) PrescriptionDoc
AU2012902137A0 (en) Hydro-Ice
AU2012902080A0 (en) EzyChange
AU2012902061A0 (en) 1Card
AU2012902021A0 (en) TriCap
AU2012901899A0 (en) Bikedicators
AU2012901881A0 (en) Hammers-extended
AU2012901846A0 (en) Cara - suite
AU2012901814A0 (en) Motostrap
AU2012901671A0 (en) Lootcase
AU2012901667A0 (en) Camber-Inducer
AU2012901606A0 (en) Quadralock
AU2012901593A0 (en) Texta
AU2012901552A0 (en) AirPowerVehicleAssist
AU2012901540A0 (en) Sungoggs
AU2012901175A0 (en) tri-guard
AU2012901408A0 (en) Skydorm
AU2012901403A0 (en) Rigitape

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181003

MKLA Lapsed

Effective date: 20221031